相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effect on low HER2 (1+) expressing tumor cells of the trifunctional antibody ertumaxomab
M. Jäger et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer
H. J. Burstein et al.
ANNALS OF ONCOLOGY (2008)
Construction of optimized bispecific antibodies for selective activation of the death receptor CD95
Tania Herrmann et al.
CANCER RESEARCH (2008)
Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy
Stephen Johnston et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer
Henry L. Gomez et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Adoptive therapy of head and neck squamous cell carcinoma with antibody coated immune cells: a pilot clinical trial
Herbert Riechelmann et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Induction of adaptive anti-HER2/neu immune responses in a phase 1B/2 trial of 2B1 bispecific murine monoclonal antibody in metastatic breast cancer (E3194):: A trial coordinated by the Eastern Cooperative Oncology Group
Hossein Borghaei et al.
JOURNAL OF IMMUNOTHERAPY (2007)
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
Charles E. Geyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer
Philipp Kiewe et al.
CLINICAL CANCER RESEARCH (2006)
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer
H Joensuu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Immunotherapy of malignant ascites with trifunctional antibodies
MM Heiss et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
EH Romond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcγRI x anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer
R Repp et al.
BRITISH JOURNAL OF CANCER (2003)
Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody
P Ruf et al.
BLOOD (2001)
Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (αEpCAM x αCD3)
R Riesenberg et al.
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
分享论文
